P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma
1998

Drug Resistance in Osteosarcoma

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): SD Shnyder, AJ Hayes, J Pringle, CW Archer

Primary Institution: Anatomy Unit, School of Molecular & Medical Biosciences, Cardiff, UK; Institute of Orthopaedics, University College London, England

Hypothesis

Does the expression of P-glycoprotein and metallothionein correlate with patient survival in osteosarcoma?

Conclusion

Lack of expression of P-glycoprotein and metallothionein does not appear to confer any advantage in terms of patient survival in osteosarcoma.

Supporting Evidence

  • The study assessed the expression of P-glycoprotein and metallothionein in biopsy material from 18 patients.
  • Statistical analysis showed no significant differences in survival rates between expressors and non-expressors of P-glycoprotein and metallothionein.
  • Previous studies have shown conflicting results regarding the correlation between P-glycoprotein expression and therapy response.

Takeaway

This study looked at whether certain proteins in cancer cells affect how well patients with osteosarcoma respond to treatment, and found that they don't seem to make a difference.

Methodology

Immunohistochemical assessment of P-glycoprotein and metallothionein expression in biopsy samples from patients with osteosarcoma, followed by statistical analysis of survival data.

Limitations

The study only included patients with known 5-year follow-up data, which may limit the generalizability of the findings.

Participant Demographics

Patients with clinically diagnosed high-grade malignant osteosarcoma.

Statistical Information

P-Value

0.81 for C219; 0.88 for E9

Statistical Significance

p=0.81 for C219; p=0.88 for E9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication